 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults (clinicaltrials.gov) - Jul 9, 2025
P1, N=68, Completed, Sponsor: ANRS, Emerging Infectious Diseases
Active, not recruiting --> Completed
- CD40.HIVRI.Env / ANRS
Unadjuvanted CD40.HIVRI.ENV Vaccine Late Boost Induces Durable Immune Responses: ANRS/VRI06 Trial (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_787;
P1
Active, not recruiting --> Completed The ANRS/VRI06 phase I trial (NCT04842682) enrolled 72 non HIV-infected volunteers to receive either 0
- | CD40.HIVRI.Env / ANRS
Trial completion: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (clinicaltrials.gov) - Dec 17, 2024
P1, N=72, Completed, Sponsor: ANRS, Emerging Infectious Diseases
The ANRS/VRI06 phase I trial (NCT04842682) enrolled 72 non HIV-infected volunteers to receive either 0 Active, not recruiting --> Completed
- || CD40.HIVRI.Env / ANRS
P1 data, Journal: Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06). (Pubmed Central) - Dec 9, 2024
P1
Active, not recruiting --> Completed Volunteers were randomized (5:1 active versus placebo) in groups receiving either 0.3, 1.0, or 3.0
- | CD40.HIVRI.Env / ANRS
Enrollment closed, Trial primary completion date: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (clinicaltrials.gov) - Aug 13, 2024
P1, N=72, Active, not recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Volunteers were randomized (5:1 active versus placebo) in groups receiving either 0.3, 1.0, or 3.0 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Nov 2024
- || DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Clinical, P1/2 data, Journal: Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial. (Pubmed Central) - Jun 25, 2024
P1/2
The vaccine regimens were generally well tolerated. Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120 elicited the strongest humoral responses; AS01B-adjuvanted regimens elicited stronger CD4+ T-cell responses, justifying further evaluation.ClinicalTrials.gov registration: NCT02915016, registered 26 September 2016.
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Journal: SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses. (Pubmed Central) - Jun 21, 2024
The HVTN 105 vaccine clinical trial tested four combinations of two immunogens - the DNA vaccine DNA-HIV-PT123, and the protein vaccine AIDSVAX B/E...In the complex HVTN105 dataset, alternative analysis methods increased sensitivity of the detection of antigen-specific T cells; increased the number of identified vaccine responders; identified a small IL-21-producing T cell population; and demonstrated significant correlations between specific T cell populations and serum antibody responses. Multiple analysis strategies may be valuable for extracting the most information from large, complex studies.
- Comparative analysis of antibody responses to CN54gp140 and AIDSVAX B/E in the PrEPVacc trial () - Jun 18, 2024 - Abstract #AIDS2024AIDS_3977;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment closed: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults (clinicaltrials.gov) - Jan 2, 2024
P1, N=68, Active, not recruiting, Sponsor: ANRS, Emerging Infectious Diseases
If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference. Recruiting --> Active, not recruiting
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment open, Trial completion date, Trial primary completion date: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults (clinicaltrials.gov) - Sep 22, 2023
P1, N=70, Recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2022 --> Sep 2024
- | CD40.HIVRI.Env / ANRS
Trial completion date, Trial primary completion date: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (clinicaltrials.gov) - Sep 14, 2022
P1, N=72, Recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2022 --> Sep 2024 Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2022 --> Sep 2023
- |||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial completion date, Trial primary completion date: PrEPVacc: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (clinicaltrials.gov) - Jul 1, 2022
P2b, N=1668, Enrolling by invitation, Sponsor: MRC/UVRI and LSHTM Uganda Research Unit
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2022 --> Sep 2023 Not yet recruiting --> Enrolling by invitation | Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases, VRC01 / Acuitas Therap
Journal: Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa. (Pubmed Central) - Dec 14, 2021
P1, P1/2,
Current trials attract participants with lower educational levels, which may be driven by the site locations, current community mobilisation strategies and research site opening hours. The sites could consider more flexible working hours to accommodate working participants and find ways to connect participants to educational support and opportunities to upgrade education levels for the current clientele.
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Phase classification: Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX (clinicaltrials.gov) - Oct 15, 2021
P1b, N=104, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The sites could consider more flexible working hours to accommodate working participants and find ways to connect participants to educational support and opportunities to upgrade education levels for the current clientele. Phase classification: P1 --> P1b
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Phase classification: Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Oct 15, 2021
P1b, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P1 --> P1b Phase classification: P1 --> P1b
- | CD40.HIVRI.Env / ANRS
Enrollment open: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (clinicaltrials.gov) - Apr 29, 2021
P1, N=72, Recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults (clinicaltrials.gov) - Apr 13, 2021
P1, N=70, Not yet recruiting, Sponsor: ANRS, Emerging Infectious Diseases
- | CD40.HIVRI.Env / ANRS
New P1 trial: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (clinicaltrials.gov) - Apr 12, 2021
P1, N=72, Not yet recruiting, Sponsor: ANRS, Emerging Infectious Diseases
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 24, 2020
P1/2, N=334, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
New P2b trial: PrEPVacc: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (clinicaltrials.gov) - Aug 26, 2019
P2b, N=1668, Not yet recruiting, Sponsor: MRC/UVRI Uganda Research Unit on Aids
- ||| DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date, Trial primary completion date: HVTN111: Safety and Immune Response to a Clade C DNA HIV Vaccine (clinicaltrials.gov) - Jun 21, 2019
P1, N=132, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Sep 2017 --> Jul 2018 | Trial primary completion date: Sep 2017 --> Jul 2018
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - May 30, 2019
P1/2, N=334, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial completion date: Sep 2017 --> Jul 2018 | Trial primary completion date: Sep 2017 --> Jul 2018 Trial primary completion date: Jan 2020 --> Aug 2019
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date: Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial (clinicaltrials.gov) - Feb 7, 2019
P1, N=49, Completed, Sponsor: EuroVacc Foundation
Trial primary completion date: Jan 2020 --> Aug 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion, Enrollment change: Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Nov 27, 2018
P1, N=143, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018 Active, not recruiting --> Completed | N=209 --> 143
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Oct 30, 2018
P1/2, N=334, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=209 --> 143 Trial primary completion date: Oct 2018 --> Jan 2020
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Aug 1, 2018
P1/2, N=334, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2018 --> Jan 2020 Recruiting --> Active, not recruiting
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=334, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Oct 2018
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial (clinicaltrials.gov) - Jan 5, 2018
P1, N=49, Active, not recruiting, Sponsor: EuroVacc Foundation
- || DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment status: HVTN111: Safety and Immune Response to a Clade C DNA HIV Vaccine (clinicaltrials.gov) - Jan 18, 2017
P1, N=132, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jan 2018 --> Oct 2018 Enrolling by invitation --> Recruiting
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Jan 4, 2017
P1/2, N=334, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Recruiting Not yet recruiting --> Recruiting
- ||| DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: HVTN111: Safety and Immune Response to a Clade C DNA HIV Vaccine (clinicaltrials.gov) - Dec 20, 2016
P1, N=132, Enrolling by invitation, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1/2 trial: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=334, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment change, Trial withdrawal: Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa (clinicaltrials.gov) - Sep 23, 2016
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=264 --> 0 | Not yet recruiting --> Withdrawn
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion, Trial primary completion date: Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX (clinicaltrials.gov) - Apr 13, 2016
P1, N=104, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=264 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2015
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 18, 2016
P1, N=209, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Dec 2014 --> Sep 2014
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Trial completion: EV06: Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS (clinicaltrials.gov) - Jan 22, 2016
P1, N=72, Completed, Sponsor: EuroVacc Foundation
Trial primary completion date: Dec 2014 --> Sep 2014 Recruiting --> Completed
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment change, Trial withdrawal, Trial primary completion date: Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Nov 21, 2015
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=180 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Apr 2014
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases, ITC-6146RO / IntoCell
Trial completion: Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 25, 2015
P1, N=96, Completed, Sponsor: HIV Vaccine Trials Network
N=180 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2015 --> Apr 2014 Active, not recruiting --> Completed
- ||| DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: EV06: Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS (clinicaltrials.gov) - Mar 3, 2015
P1, N=72, Recruiting, Sponsor: EuroVacc Foundation
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX (clinicaltrials.gov) - Jan 28, 2015
P1, N=104, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases, ITC-6146RO / IntoCell
Trial primary completion date: Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Oct 17, 2014
P1, N=96, Active, not recruiting, Sponsor: HIV Vaccine Trials Network
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2014 --> Dec 2014
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX (clinicaltrials.gov) - Aug 4, 2014
P1, N=104, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Feb 24, 2014
P1, N=209, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Oct 15, 2013
P1, N=180, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Sep 3, 2013
P1, N=96, Active, not recruiting, Sponsor: HIV Vaccine Trials Network
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa (clinicaltrials.gov) - Aug 21, 2013
P1, N=264, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Feb 25, 2013
P1, N=96, Active, not recruiting, Sponsor: HIV Vaccine Trials Network
- DNA-HIV-PT123 vaccine / EuroVacc, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Feb 3, 2013
P1, N=209, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)